Search results
Results from the WOW.Com Content Network
The drug policy of the Philippines is guided by the Comprehensive Dangerous Drugs Act of 2002 and is implemented by the Dangerous Drugs Board with its implementing arm, the Philippine Drug Enforcement Agency along with other member agencies. Aside from regulating and prohibiting the usage, sale, production of certain drugs, the 2002 law is ...
The law took effect on June 22, 2002, 15 days after it was signed by Gloria Macapagal Arroyo.Its primary implementing agency is the Philippine Drug Enforcement Agency.The list of illegal drugs may be modified by the DDB through a proceeding initiated by the PDEA, the Department of Health, or any petition by a concerned party.
Year of discovery Name of the drug Year when the synthesis mechanism was developed Year that was Patented Governmental approval Patented expired 1901: Adrenaline: Jōkichi Takamine, 1901: 1901: 1901: N/A (Natural Hormone) 1906: Oxytocin: Discovered by Henry Hallett Dale, synthesized by Vincent du Vigneaud in 1952: 1925: 1926: N/A (Natural ...
At the time when the Republic Act 6425, also known as the Dangerous Drugs Act of 1972, was approved on March 30, 1972, there were 20,000 drug users and marijuana was the most preferred illegal drug among users in the country.
The Philippine Senate Committee on Public Order and Dangerous Drugs is a standing committee of the Senate of the Philippines. It was known as the Committee on Public Order and Illegal Drugs until November 9, 2010.
One of Indonesia’s most-wanted drug suspects has been arrested in the Philippines after an international manhunt and efforts were underway to have the suspect extradited to Jakarta to face ...
Dirty drug; Discovery and development of 5α-reductase inhibitors; Discovery and development of antiandrogens; Discovery and development of bisphosphonates; Discovery and development of cephalosporins; Discovery and development of direct Xa inhibitors; Discovery and development of integrase inhibitors; Discovery and development of statins
Biotech firm Iambic Therapeutics unveiled on Tuesday what it says is a breakthrough artificial intelligence model that could drastically reduce the time and money needed to develop new drugs.